Clinical Trial Update: Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a checkpoint inhibitor in combination with erlotinib or crizotinib for EGFR- or ALK-mutated stage IV non-small cell lung cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Xalkori (crizotinib)

Snippet

Sponsor: University of Utah | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED